Search Result

Pathways Recommended:	Immunology/Inflammation

Results for "

Hypothalamic inflammation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	NOD-like Receptor (NLR) (2) Toll-like Receptor (TLR) (1)
By Research Areas:	Inflammation/Immunology (3) Metabolic Disease (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-D1056A3

Lipopolysaccharides, from E. coli O26:B6 LPS, from Escherichia coli (O26:B6)	Toll-like Receptor (TLR)	Inflammation/Immunology
Lipopolysaccharides, from E. coli (Escherichia coli) O26:B6 are lipopolysaccharide endotoxins and TLR-4 activators derived from E. coli, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from E. coli O26:B6 exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A, and can be recognized by the core-specific monoclonal antibody MAb J8-4C10. Lipopolysaccharides, from E. coli O26:B6 can promote an increase in pro-inflammatory cytokines in plasma, thereby triggering hypothalamic-pituitary-adrenal (HPA) activation and leading to adrenal oxidative damage. The pathogenic effects of Lipopolysaccharides, from E. coli O26:B6 can be used to construct various models, such as cellular inflammation models, sepsis, acute lung injury models, adrenal dysfunction models, and bladder infection models, etc . It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.

HY-179131

TN-783	NOD-like Receptor (NLR)	Metabolic Disease Inflammation/Immunology
TN-783 is an orally active, brain-penetrant NLRP3 (IC₅₀ = 19.3 nM) inhibitor. TN-783 enhances the effects of the GLP-1 receptor agonist semaglutide. TN-783 requires sustained targeted action, not permanent metabolic remodeling. TN-783 can be used for the study of obesity .

HY-179132

TN-101	NOD-like Receptor (NLR)	Metabolic Disease Inflammation/Immunology
TN-101 is an orally active NLRP3 inhibitor (IC₅₀ = 29.8 nM). TN-101 can be used for the study of obesity .

Cat. No.	Product Name	Type

HY-D1056A3

Lipopolysaccharides, from E. coli O26:B6 LPS, from Escherichia coli (O26:B6)	Biochemical Assay Reagents
Lipopolysaccharides, from E. coli (Escherichia coli) O26:B6 are lipopolysaccharide endotoxins and TLR-4 activators derived from E. coli, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from E. coli O26:B6 exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A, and can be recognized by the core-specific monoclonal antibody MAb J8-4C10. Lipopolysaccharides, from E. coli O26:B6 can promote an increase in pro-inflammatory cytokines in plasma, thereby triggering hypothalamic-pituitary-adrenal (HPA) activation and leading to adrenal oxidative damage. The pathogenic effects of Lipopolysaccharides, from E. coli O26:B6 can be used to construct various models, such as cellular inflammation models, sepsis, acute lung injury models, adrenal dysfunction models, and bladder infection models, etc . It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.

Lipopolysaccharides, from E. coli O26:B6

LPS, from Escherichia coli (O26:B6)

Biochemical Assay Reagents

Lipopolysaccharides, from E. coli (Escherichia coli) O26:B6 are lipopolysaccharide endotoxins and TLR-4 activators derived from E. coli, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from E. coli O26:B6 exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A, and can be recognized by the core-specific monoclonal antibody MAb J8-4C10. Lipopolysaccharides, from E. coli O26:B6 can promote an increase in pro-inflammatory cytokines in plasma, thereby triggering hypothalamic-pituitary-adrenal (HPA) activation and leading to adrenal oxidative damage. The pathogenic effects of Lipopolysaccharides, from E. coli O26:B6 can be used to construct various models, such as cellular inflammation models, sepsis, acute lung injury models, adrenal dysfunction models, and bladder infection models, etc .
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.